Command Trial Mesothelioma, Progress In The Management Of Malignant Pleural Mesothelioma In 2017 Sciencedirect

In this trial they are looking at an experimental drug called defactinib.

Donald duck coloring pages for kids. Command is a registration directed trial of lead cancer stem cell inhibitor defactinib vs 6063 in patients with malignant pleural mesothelioma a highly aggressive form of lung cancer with a. Called the command study the research will look at whether people with malignant pleural mesothelioma could benefit from defactinib a drug which is being developed to target cancer stem cells cells which may cause tumour growth. A clinical trial gives people an experimental disease.

The registration directed trial titled command control of mesothelioma with maintenance defactinib is unique because it has produced promising results in maintenance treatment in malignant pleural mesothelioma mpm patients. Mesothelioma is a rare and deadly form of cancer linked to asbestos exposure. The trial alternately called command control of mesothelioma with maintenance defactinib evaluated the use of the new drug defactinib which targets mesothelioma stem cells.

The trial is a registration directed trial for vs 6063 verastems lead cancer stem cell inhibitor defactinib and will target killing cancer stem cells. It will be a multi national trial including 11 countries enrolling around 400 patients with pleural mesothelioma. 28 that it will stop enrollment for futility in the trial of its focal adhesion kinase inhibitor drug vs 6063 or defactinib.

The second trial is part of a global trial named command control of mesothelioma with maintenance defactinib sponsored by pharmaceutical company verastem which will investigate a new drug called defactinib. It stops signals that mesothelioma cells use to divide and grow. A new drug to treat mesothelioma is currently in a phase 2 clinical trial headed by the drug company verastem inc.

The mesothelioma community received a stunning blow last week with the news that verastem is halting its command clinical trialthe company announced sept. When you and your doctor developed a mesothelioma treatment plan and talked about your long term care options you more than likely discussed the possibility of one day participating in a clinical trialif your cancer is returning in spite of surgery chemotherapy and radiation the time to start considering a clinical trial might be now. Research to discover whether an experimental drug called defactinib could be effective in treating mesothelioma has been launched by the drug company verastem.

Defactinib is a type of biological therapy. The purpose of the treatment is to prevent tumors from reappearing after the first rounds of chemotherapy with alimta cisplatin and other treatments. The researchers believe the drug could help to inhibit focal adhesion kinase fak which is critical for the cancer stem cells.

The trial is comparing defactinib with a dummy drug placebo.